Y-27632 | m-entrepreneurship.com

Product Name :
Y-27632

Search keywords :
Y-27632

drugId :
null

Target Vo:
Rho-associated kinases

Target Vo Short Name :
ROCKs

Moa_Name:
Rho-associated kinases inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Mitsubishi Pharma Corporation Pharmaceutical Technology Center

Active Company_Name :
Mitsubishi Pharma Corporation Pharmaceutical Technology Center

Active Indication_Name:
Cardiovascular Diseases

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Tixagevimab Epigenetics
Zalutumumab Purity & Documentation
CD79a Antibody: CD79a Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to CD79a. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

Author: Betaine hydrochloride

Related Posts